SG/PUT/BRISTOL-MYERS SQUIBB/50/0.1/21.03.25 | Real-time Boerse Frankfurt Warrants 09:33:50 03/06/2024 pm IST | ||
| 0.88 EUR | -7.37% |
|
| 1 month | +30.14% | ||
| 3 months | +126.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 0.88 | -7.37% |
| 31/24/31 | 0.95 | -5.00% |
| 30/24/30 | 1 | +1.01% |
| 29/24/29 | 0.99 | +1.02% |
| 28/24/28 | 0.98 | +8.89% |
Real-time Boerse Frankfurt Warrants
Last update June 03, 2024 at 09:33 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU6Q4C |
| ISIN | DE000SU6Q4C8 |
| Date issued | 08/01/2024 |
| Strike | 50 $ |
| Maturity | 21/03/2025 (291 Days) |
| Parity | 10 : 1 |
| Emission price | 0.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.02 € |
|---|---|
| Lowest since issue | 0.29 € |
| Spread | 0.01 € |
| Spread % | 1.12% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09
USD
Average target price
53.19
USD
Spread / Average Target
+29.46%
- Stock Market
- Warrants
- Warrant
